Luca Arecco, Clinical Research Fellow at ESMO, shared a post on X:
“One size does not fit all! Just published in JNCI.
A suggesting that TROP2 expression may help identify pts deriving the greatest benefit from TROP2-ADCs, reinforcing the need for predictive biomarkers to optimize pts selection! Thank you and congrats.”
Title: Impact of trop-2 expression on the efficacy of trop-2–targeted antibody–drug conjugates in metastatic breast cancer: a systematic review and meta-analysis
Authors: Roberto Buonaiuto, Martina Pagliuca, Alessandra Longobardi, Maria Letizia Cataldo, Luca Arecco, Riccardo Gerosa, Gabriella Gentile, Aldo Caltavituro, Ines Barone, Bengisu Karakose, Elisa Agostinetto, Christos Sotiriou, Michelino De Laurentiis, Evandro De Azambuja, Carmine De Angelis
Read the full article.
Germline Multigene Testing May Identify Higher-Risk Invasive Lobular Breast Cancer
